Skip to content
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
How a 14-member biotech spent just $10M on a product global pharma wants to lap up
Home
update
How a 14-member biotech spent just $10M on a product global pharma wants to lap up
Post Author:
eyetem@admin
Post navigation
Previous Post
Eyestem announces interim safety and efficacy data from ongoing Phase I trial using Eyecyte-RPE for the treatment of Geographic Atrophy patients, in an International Conference “The Future is Here II, Exploring New Frontiers of Ocular Research”, organized by LV Prasad Eye Institute, Hyderabad b/w Jan 9-12.
Next Post
Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients
